Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 ACADIA PharmaceuticalsUnited TherapeuticsSchrödingerIonis PharmaceuticalsAscendis Pharma A/S
SymbolNASDAQ:ACADNASDAQ:UTHRNASDAQ:SDGRNASDAQ:IONSNASDAQ:ASND
Price Information
Current Price$20.28$201.40$73.52$39.89$120.22
52 Week RangeHoldBuyBuyHoldBuy
MarketRank™
Overall Score1.91.51.51.61.5
Analysis Score4.22.52.44.13.5
Community Score3.22.23.52.32.6
Dividend Score0.00.00.00.00.0
Ownership Score1.71.70.81.70.8
Earnings & Valuation Score0.61.30.60.00.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyHoldBuy
Consensus Price Target$32.76$219.57$85.50$57.45$187.67
% Upside from Price Target61.56% upside9.02% upside16.29% upside44.03% upside56.10% upside
Trade Information
Market Cap$3.38 billion$9.07 billion$5.45 billion$5.74 billion$6.55 billion
Beta1.440.52N/A1.420.77
Average Volume2,184,863389,4781,108,9991,221,907207,189
Sales & Book Value
Annual Revenue$339.08 million$1.45 billion$85.54 million$1.12 billion$14.98 million
Price / Sales9.576.1960.175.00431.36
CashflowN/AN/AN/A$1.62 per shareN/A
Price / CashN/AN/AN/A24.55N/A
Book Value$4.54 per share$63.36 per share($15.25) per share$11.98 per share$15.87 per share
Price / Book4.473.18-4.823.337.58
Profitability
Net Income$-235,260,000.00$-104,500,000.00$-24,570,000.00$303.26 million$-244,180,000.00
EPS($1.60)($2.39)N/A$2.08($5.25)
Trailing P/E RatioN/A19.050.0083.10N/A
Forward P/E RatioN/A17.38N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-63.92%33.25%-19.92%7.82%-4,042.79%
Return on Equity (ROE)-40.35%15.48%-7.25%6.57%-55.72%
Return on Assets (ROA)-34.72%11.31%-5.33%3.39%-49.42%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.24%N/A0.51%N/A
Current Ratio7.95%7.22%15.81%10.37%14.80%
Quick Ratio7.86%6.88%15.81%10.28%14.80%
Ownership Information
Institutional Ownership Percentage93.54%90.09%41.29%84.14%N/A
Insider Ownership Percentage27.70%10.90%N/A2.40%40.00%
Miscellaneous
Employees601950445757330
Shares Outstanding160.05 million44.54 million70.01 million140.86 million53.75 million
Next Earnings Date5/6/2021 (Estimated)5/5/2021 (Estimated)5/12/2021 (Estimated)5/5/2021 (Estimated)5/18/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
After A -26.88% Fall This Year Is Ascendis Pharma A/S (NASDAQ:ASND) A Better Buy Than Others?After A -26.88% Fall This Year Is Ascendis Pharma A/S (NASDAQ:ASND) A Better Buy Than Others?
marketingsentinel.com - April 17 at 10:56 AM
RSI Alert: Ascendis Pharma (ASND) Now OversoldRSI Alert: Ascendis Pharma (ASND) Now Oversold
nasdaq.com - April 15 at 8:08 PM
Oppenheimer Downgrades Ascendis Pharma A/S (NASDAQ:ASND) to Market PerformOppenheimer Downgrades Ascendis Pharma A/S (NASDAQ:ASND) to Market Perform
americanbankingnews.com - March 30 at 8:36 AM
Ascendis Pharma A/S (NASDAQ:ASND) Rating Lowered to Market Perform at OppenheimerAscendis Pharma A/S (NASDAQ:ASND) Rating Lowered to Market Perform at Oppenheimer
marketbeat.com - March 30 at 7:53 AM
Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism at ENDO 2021Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism at ENDO 2021
finance.yahoo.com - March 23 at 9:27 AM
Ascendis Pharma A/S Announces Participation at Oppenheimer 31st Annual Healthcare ConferenceAscendis Pharma A/S Announces Participation at Oppenheimer 31st Annual Healthcare Conference
benzinga.com - March 15 at 7:12 AM
Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to ...Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to ...
apnews.com - March 11 at 5:58 AM
Ascendis Pharma A/S (ASND) Q4 2020 Earnings Call TranscriptAscendis Pharma A/S (ASND) Q4 2020 Earnings Call Transcript
finance.yahoo.com - March 11 at 5:58 AM
Ascendis Pharma A/S Reports Full Year 2020 Financial ResultsAscendis Pharma A/S Reports Full Year 2020 Financial Results
finance.yahoo.com - March 10 at 6:05 PM
Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine DiseasesAscendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases
finance.yahoo.com - March 10 at 8:04 AM
Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine DiseasesAscendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases
finance.yahoo.com - March 10 at 8:04 AM
Earnings Preview for Ascendis PharmaEarnings Preview for Ascendis Pharma
finance.yahoo.com - March 9 at 2:34 PM
Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10
finance.yahoo.com - March 4 at 6:59 PM
Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease ...Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease ...
apnews.com - February 27 at 4:01 AM
Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021
finance.yahoo.com - February 26 at 7:38 AM
Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare ConferenceAscendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference
finance.yahoo.com - February 18 at 5:36 PM
Ascendis Pharma A/S Announces Equity Investment in VISEN PharmaceuticalsAscendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals
finance.yahoo.com - January 8 at 11:51 PM
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater ChinaVISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
finance.yahoo.com - January 8 at 11:51 PM
Ascendis Pharma Invests $12.5 Mln In VISEN Pharma Ascendis Pharma Invests $12.5 Mln In VISEN Pharma
markets.businessinsider.com - January 8 at 9:34 PM
Ascendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare ConferenceAscendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare Conference
benzinga.com - January 4 at 7:29 AM
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate ...Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate ...
apnews.com - December 31 at 8:02 AM
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon(TM) TLR7/8 Agonist Clinical ProgramAscendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon(TM) TLR7/8 Agonist Clinical Program
stockhouse.com - December 30 at 7:24 PM
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon(TM) TLR7/8 Agonist Clinical ProgramAscendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon(TM) TLR7/8 Agonist Clinical Program
stockhouse.com - December 30 at 7:24 PM
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical ProgramAscendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program
finance.yahoo.com - December 30 at 7:24 PM
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical ProgramAscendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program
finance.yahoo.com - December 30 at 7:24 PM
Implied Volatility Surging for Ascendis Pharma (ASND) Stock OptionsImplied Volatility Surging for Ascendis Pharma (ASND) Stock Options
finance.yahoo.com - December 30 at 2:04 PM
DateCompanyBrokerageAction
4/13/2021ACADIA PharmaceuticalsThe Goldman Sachs GroupReiterated Rating
4/13/2021ACADIA PharmaceuticalsJefferies Financial GroupReiterated Rating
4/13/2021ACADIA PharmaceuticalsMizuhoReiterated Rating
4/13/2021ACADIA PharmaceuticalsCanaccord GenuityReiterated Rating
4/13/2021ACADIA PharmaceuticalsMorgan StanleyLower Price Target
4/13/2021ACADIA PharmaceuticalsHC WainwrightReiterated Rating
4/6/2021ACADIA PharmaceuticalsSVB LeerinkLower Price Target
4/6/2021ACADIA PharmaceuticalsCantor FitzgeraldBoost Price Target
4/5/2021ACADIA PharmaceuticalsRaymond JamesDowngrade
4/5/2021ACADIA PharmaceuticalsNeedham & Company LLCLower Price Target
3/16/2021ACADIA PharmaceuticalsBank of AmericaReiterated Rating
3/15/2021ACADIA PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated Rating
3/15/2021ACADIA PharmaceuticalsStifel NicolausReiterated Rating
3/15/2021ACADIA PharmaceuticalsGuggenheimReiterated Rating
4/14/2021United TherapeuticsJPMorgan Chase & Co.Boost Price Target
3/1/2021United TherapeuticsCredit Suisse GroupBoost Price Target
2/25/2021United TherapeuticsWedbushBoost Price Target
2/16/2021United TherapeuticsOppenheimerBoost Price Target
1/20/2021United TherapeuticsCowenBoost Price Target
1/20/2021United TherapeuticsLADENBURG THALM/SH SHBoost Price Target
3/24/2021SchrödingerBMO Capital MarketsLower Price Target
4/5/2021Ionis PharmaceuticalsUBS GroupReiterated Rating
3/23/2021Ionis PharmaceuticalsBarclaysLower Price Target
3/23/2021Ionis PharmaceuticalsRoyal Bank of CanadaLower Price Target
3/22/2021Ionis PharmaceuticalsPiper SandlerLower Price Target
12/17/2020Ascendis Pharma A/SBerenberg BankInitiated Coverage
11/12/2020Ascendis Pharma A/SWells Fargo & CompanyBoost Price Target
5/20/2020Ascendis Pharma A/SCSFBBoost Price Target
(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.